| Filed On | Filing |
|---|---|
| 17 Oct 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective O... |
| 26 Oct 2020 |
8-K/A: Submission of Matters to a Vote of Security Holders
On June 5, 2020, Allogene Therapeutics, Inc. (the "Company") held its 2020 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 21, 2020, the record date for the Annual Meeting, 125,310,920 shares of common stock were outst... |
Loading...